Thomson Medical Group Limited (SGX: A50) is one of the few Singapore-listed healthcare groups that has deliberately turned itself into a three-country hospital platform. What began in 1979 as a single maternity hospital on Thomson Road is now a group spanning Singapore, Malaysia and Vietnam, with revenue of S$420.1 million in the financial year ended 30 June 2026 and a RM18 billion healthcare-led property project in Johor on its drawing board. This company profile explains how Thomson Medical got here, what it owns, how the numbers have moved, and why its next three years matter for anyone tracking healthcare M&A in Southeast Asia.
Key Takeaways
- Thomson Medical Group is an SGX Mainboard-listed private healthcare group (ticker A50) controlled by Singaporean billionaire Peter Lim, with hospitals and specialist clinics in Singapore, Malaysia and Vietnam.
- The group’s roots are Thomson Medical Centre, a Singapore maternity hospital founded in 1979 by Dr Cheng Wei Chen; Peter Lim bought it in 2010 and folded it, plus a 70.36% stake in Malaysia’s TMC Life Sciences, into the listed Rowsley Ltd through a reverse takeover of roughly S$1.6 billion.
- In December 2023 Thomson Medical completed the acquisition of 100% of FV Hospital in Ho Chi Minh City for up to US$381.4 million, the largest healthcare deal in Vietnam’s history.
- For FY2026 (year ended 30 June 2026) the group reported revenue of S$420.1 million (+6.4%), EBITDA of S$67.3 million (+23.2%) and a net loss narrowed by 40.8% to S$27.8 million, but net debt stood at about S$994 million.
- In August 2025 the group launched Johor Bay, an RM18 billion (about US$4.3 billion) healthcare-led mixed-use development in the Johor-Singapore Special Economic Zone anchored by the planned 1,000-bed Thomson Hospital Iskandariah.
Company Snapshot
| Company | Thomson Medical Group Limited |
| Listing | SGX Mainboard, ticker A50 |
| Headquarters | Singapore |
| Founded | 1979 (Thomson Medical Centre); listed group formed via reverse takeover of Rowsley Ltd |
| Controlling shareholder | Peter Lim and family |
| Markets | Singapore, Malaysia, Vietnam |
| Core specialties | Obstetrics and gynaecology, paediatrics, fertility/IVF, multi-disciplinary tertiary care, oncology |
| Key brands | Thomson Medical Centre, Thomson Hospital Kota Damansara, Thomson Fertility (formerly TMC Fertility), FV Hospital, Thomson Chinese Medicine |
| FY2026 revenue | S$420.1 million |
| Website | thomsonmedical.com |
From a Maternity Hospital to a Listed Regional Group
1979–2010: Dr Cheng Wei Chen’s Thomson Medical Centre
Thomson Medical Centre was established in Singapore in 1979 by obstetrician Dr Cheng Wei Chen. It built its reputation almost entirely around women and children: obstetrics, gynaecology, paediatrics and, crucially, fertility. The hospital recorded Singapore’s first IVF triplets in 1988 and what was reported as Asia’s first surviving IVF quadruplets in 1989. For a generation of Singaporean families, “born at Thomson” became a shorthand for a private, premium birth experience. That brand equity is the single most important asset the group still owns, and it explains why the Thomson name has been carried into every market the group has entered since.
2010: Peter Lim Buys In
In 2010, Singaporean billionaire Peter Lim, best known outside Asia as the owner of Spanish football club Valencia CF, acquired Thomson Medical Centre in a deal valued at around S$400 million, which included buying out Dr Cheng’s 39.34% stake for S$201.9 million. The hospital was taken private and Lim began assembling a broader healthcare portfolio around it, most notably a controlling stake in Malaysia’s TMC Life Sciences Berhad, the operator of what is now Thomson Hospital Kota Damansara in Selangor and the TMC Fertility chain.
2017–2019: The Rowsley Reverse Takeover
The present-day listed group was created through a reverse takeover. Rowsley Ltd, Lim’s SGX-listed investment vehicle, agreed in 2017 to acquire 100% of Thomson Medical Pte Ltd and a 70.36% stake in TMC Life Sciences Berhad from Lim in a transaction of roughly S$1.6 billion. On completion Rowsley was renamed Thomson Medical Group Limited. The structure brought the Singapore maternity franchise and the Malaysian hospital and fertility assets under one listed roof, but it also concentrated ownership: Lim and his family remain the controlling shareholder, and the free float is thin by SGX standards. That fact shapes almost every strategic decision the group makes, from how it funds acquisitions to how the market prices its shares.
What Thomson Medical Owns Today
Singapore: The Women-and-Children Franchise
In Singapore the group operates Thomson Medical Centre, a 187-bed private hospital focused on obstetrics, gynaecology and paediatrics, alongside a network of specialist clinics, fertility services, paediatric clinics, and Thomson Chinese Medicine (TCM) outlets. According to the group’s FY2025 results release, Singapore operations achieved record core revenue of S$190.4 million in the year ended June 2025. Singapore is the profit engine and the brand anchor, but it is also a mature market with a low birth rate, so growth here is increasingly about specialist clinics and ancillary services rather than more deliveries.
Malaysia: Kota Damansara, Fertility and Oncology
In Malaysia the group operates through TMC Life Sciences: Thomson Hospital Kota Damansara, which has been expanded to a capacity of up to 554 beds, and Thomson Fertility, the IVF chain founded in 1994 as TMC Fertility. In January 2026 the fertility chain rebranded to Thomson Fertility and marked more than 8,500 IVF births since inception, as reported by Malay Mail. Malaysia has become the group’s fastest-improving segment: FY2026 Malaysian revenue rose 19.1% to S$125.4 million and adjusted EBITDA jumped 52.9% to S$21.4 million, driven by a full-year contribution from its oncology centre, according to the group’s results coverage.
Vietnam: FV Hospital
Vietnam entered the portfolio in December 2023, when Thomson Medical completed its acquisition of 100% of Far East Medical Vietnam Ltd, the operator of FV Hospital in Ho Chi Minh City. Founded by French physicians in 2003, FV Hospital is a multi-disciplinary tertiary hospital of about 220 beds with a network of clinics and a patient base of expatriates and affluent Vietnamese. The deal value was up to US$381.4 million, comprising US$359.6 million upfront and a US$21.8 million earn-out, and Forbes described it as the biggest healthcare deal in Vietnam’s history. We covered the transaction in detail in Thomson Medical’s US$381 Million FV Hospital Buy.
Financial Performance: Growing Revenue, Shrinking Losses, Heavy Debt
Thomson Medical’s recent numbers tell a story of a group digesting a large acquisition. In FY2025 (year ended 30 June 2025) revenue grew 12.4% to S$394.7 million as FV Hospital contributed a full year for the first time, according to the group’s results release filed on SGX. Group core revenue has grown about 73% over five years, from S$228.5 million in FY2021. The group nonetheless posted a FY2025 net loss of about S$47 million, which it attributed largely to a one-off, non-cash goodwill impairment on the Vietnam business amid macroeconomic headwinds, plus continued investment spending, as reported by The Edge Singapore.
FY2026 showed clear operating improvement. Revenue rose 6.4% to S$420.1 million, EBITDA climbed 23.2% to S$67.3 million, the EBITDA margin widened to 16.0% from 13.8%, and the net loss narrowed 40.8% to S$27.8 million. Net operating cash flow improved to S$71.0 million from S$60.4 million. The weak spot is the balance sheet: net debt edged up to about S$994 million, equivalent to roughly 1.9 times equity and 14.8 times trailing EBITDA, according to the group’s FY2026 disclosures summarised by TipRanks in August 2026. Credit analysts have flagged near-term refinancing as the key risk for the group’s bonds.
| Metric | FY2025 (to Jun 2025) | FY2026 (to Jun 2026) |
|---|---|---|
| Revenue | S$394.7m (+12.4%) | S$420.1m (+6.4%) |
| EBITDA | about S$54.6m | S$67.3m (+23.2%) |
| Net loss | about S$47m | S$27.8m (-40.8%) |
| Malaysia revenue | S$105.3m | S$125.4m (+19.1%) |
| Net debt | n/a | about S$994m |
M&A and Investment Track Record
Thomson Medical’s corporate history is unusually deal-driven for a hospital operator. Three transactions define it:
- Thomson Medical Centre buyout (2010): Peter Lim acquires the hospital for about S$400 million, including Dr Cheng Wei Chen’s 39.34% stake for S$201.9 million.
- Rowsley reverse takeover (announced 2017, completed 2019): about S$1.6 billion, injecting Thomson Medical Pte Ltd and 70.36% of TMC Life Sciences into Rowsley, renamed Thomson Medical Group.
- FV Hospital acquisition (announced July 2023, completed December 2023): 100% of Far East Medical Vietnam for up to US$381.4 million, funded by internal resources and debt. See our full FV Hospital deal analysis.
The fourth “deal” is really an investment programme. On 25 August 2025 the group launched Johor Bay, a 26-acre (10.52-hectare) development within the Johor-Singapore Special Economic Zone, about 1.2 km from the upcoming Bukit Chagar RTS Link station, with a gross development value of RM18 billion, according to EdgeProp. The anchor is Thomson Hospital Iskandariah, now planned at 1,000 beds, up from the 500 beds originally envisaged, surrounded by specialist suites, aged care, a life sciences tower, a 47-storey luxury residential tower, a five-star hotel and commercial space. Bloomberg reported that Thomson Medical shares jumped as much as 39% intraday on the announcement, to their highest since April 2023.
Healthcare consolidation is a theme across the region. For comparison, see how Astra deepened its digital-health bet in Astra’s IDR 900 billion Halodoc top-up, and how retail pharmacy consolidated in Malaysia through the BIG Pharmacy–Caring merger. More deals and company profiles are collected on our M&A and Investment Insights hub.
Competitive Position and Key Risks
Strengths. Thomson owns a genuine niche brand in maternity and fertility, a segment where patients choose a hospital emotionally and stay loyal across multiple births. Its fertility franchise in Malaysia has decades of clinical track record. FV Hospital gives it a scarce, licensed, foreign-founded tertiary hospital in Vietnam’s largest city, which would take years to replicate organically.
Weaknesses. The group is small next to regional giants such as IHH Healthcare, and it has reported net losses in both FY2025 and FY2026 while it digests the FV Hospital purchase. Leverage of about 14.8 times trailing EBITDA leaves little room for error, especially with a capital-hungry Johor project ahead.
Risks to watch. Bond refinancing over the next 12–24 months; execution and funding of Johor Bay, including how much is funded by property sales versus balance sheet; Vietnam’s macroeconomic conditions, which already triggered one goodwill impairment; Singapore’s falling birth rate; and governance questions that come with a thin free float and related-party links to a controlling shareholder with extensive other business interests.
My Take
My opinion: Thomson Medical is no longer really a hospital company. It is a Peter Lim platform that uses a trusted hospital brand as the anchor for bigger, riskier bets, and investors should analyse it that way.
Look at the sequence. Lim bought a beloved maternity hospital in 2010, used it to build a listed vehicle through a related-party reverse takeover, used that listed vehicle and debt to pay a record price for FV Hospital, and is now using the hospital brand to anchor an RM18 billion property play in Johor. Each step is logical on its own. Together they show a pattern I have seen many times in ASEAN family-controlled groups: the operating business provides credibility and cash flow, while the real value creation, or destruction, happens in the capital-allocation decisions on top.
The good news is that the operating business is finally pulling its weight. EBITDA up 23% and the net loss cut by 41% in FY2026 is real progress, and Malaysia’s turnaround, with EBITDA up more than 50% on oncology, is the most encouraging number in the whole report. It tells me Thomson can still build specialist services that patients pay for. FV Hospital, despite the impairment, is still a trophy asset; nobody else is going to buy a better foreign-standard hospital in Ho Chi Minh City any time soon.
The bad news is the balance sheet. Net debt close to S$1 billion against S$67 million of EBITDA is not a hospital-group leverage profile; it is a property-developer leverage profile. And that is before the Johor Bay project, which is genuinely exciting as a concept, really starts consuming capital. The RTS Link and the Special Economic Zone are real tailwinds, and a 1,000-bed hospital at the Causeway could capture Singaporean patients priced out at home. But a project of this size takes a decade, and hospitals only make money once they are full.
Who wins? Patients in Johor and Vietnam, who get more premium capacity. Property buyers who believe the medical-tourism story. Peter Lim, who keeps optionality on the whole platform. Who carries the risk? Bondholders and minority shareholders, who are funding a growth plan they have very little control over. What it signals for the industry: in ASEAN healthcare, the next wave of value will be created at the intersection of hospitals, real estate and cross-border infrastructure, and Thomson is making the boldest bet on that thesis. I would watch the next refinancing and the first Johor Bay sales numbers more closely than any quarterly patient-volume figure.
Frequently Asked Questions
Who owns Thomson Medical Group?
Thomson Medical Group Limited is listed on the SGX Mainboard (ticker A50) and is controlled by Singaporean billionaire Peter Lim and his family, who acquired Thomson Medical Centre in 2010 and listed the business through a reverse takeover of Rowsley Ltd completed in 2019.
Which hospitals does Thomson Medical Group operate?
The group operates Thomson Medical Centre in Singapore, Thomson Hospital Kota Damansara and the Thomson Fertility chain in Malaysia, and FV Hospital in Ho Chi Minh City, Vietnam, plus specialist clinics and Thomson Chinese Medicine outlets.
How much did Thomson Medical pay for FV Hospital?
Thomson Medical agreed in July 2023 to buy 100% of Far East Medical Vietnam, the operator of FV Hospital, for up to US$381.4 million (US$359.6 million upfront plus a US$21.8 million earn-out). The deal completed in December 2023 and was the largest healthcare deal in Vietnam’s history.
Is Thomson Medical Group profitable?
Not yet on a net basis. For FY2026 (year ended 30 June 2026) the group reported revenue of S$420.1 million and EBITDA of S$67.3 million, but a net loss of S$27.8 million, which was 40.8% smaller than the prior year’s loss.
What is the Thomson Medical Johor Bay project?
Johor Bay is an RM18 billion (about US$4.3 billion) healthcare-led mixed-use development launched in August 2025 on a 26-acre site in the Johor-Singapore Special Economic Zone. It is anchored by the planned 1,000-bed Thomson Hospital Iskandariah and includes aged care, a life sciences tower, luxury residences and a five-star hotel.
Sources
- Thomson Medical Group, corporate profile and company history
- FV Hospital, FV Hospital is now a member of Thomson Medical Group
- Forbes, Peter Lim’s Thomson Medical to buy Vietnam hospital operator for US$381 million (11 Jul 2023)
- The Edge Singapore, Thomson Medical Group posts net loss for FY2025 as revenue grows 12.4%
- TipRanks, Thomson Medical narrows FY2026 loss as EBITDA climbs but leverage remains elevated (28 Aug 2026)
- EdgeProp, Thomson Medical Group launches RM18 bil Johor Bay development (25 Aug 2025)
- Bloomberg, Thomson Medical jumps 39% on new project in Johor special zone (26 Aug 2025)
- Malay Mail, Thomson Fertility rebrands, celebrates 8,500 IVF births since 1994 (25 Jan 2026)
Disclaimer: This article is for informational and editorial purposes only. It is not a recommendation to buy or sell any securities and does not constitute investment advice.
